Introduced recently for treatment of CHF Recombinant form of human natriuretic peptide Naturally secreted by the ventricles, increases cGMP in vascular smooth muscles and reduces arteriolar and venous tone Causes natriuresis, short t½ of 18 min Administered as bolus dose 2 µg/kg i.v. followed by continuous i.v.infusion of 0.01 to 0.03 µg/kg/min Used in acute decompensated heart failure associated with dyspnoea at rest ADR: hypotension